Filing Flows › Ironwood Pharmaceuticals (IRWD) › Q3 2026
Ironwood Pharmaceuticals (IRWD) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Ironwood Pharmaceuticals (IRWD) reported revenue of $133M for the third quarter 2026 (Q3 2026), +9% from a year earlier and +18% from the quarter before. Operating margin was 70.0%, net earnings $59.8M (45.0% of revenue).
Ironwood Pharmaceuticals, Q3 2026: revenue $133M (+9% year over year), operating margin 70.0%, net earnings $59.8M, operating cash flow $67.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $133M | +18% | +9% |
| Operating profit | $93.1M | +17% | +23% |
| Net earnings | $59.8M | +17% | +49% |
| Operating cash flow | $67.4M | +16% | +42% |
What changed
Revenue was $133.0M in Q3 2026, up 9% year over year and up 18% from the previous quarter.
Operating profit was $93.1M, a 70.0% margin (up 8.2 points year over year). Of the extra revenue versus Q3 2025, 161% reached operating profit, above the 62% margin then. Total costs fell 14% while revenue rose 9%. The fastest-growing cost line was Research & development (+26%). Net earnings were $59.8M, up 49% year over year. The effective tax rate was 31.7%.
Operating cash flow was $67.4M (up 42% year over year), 113% of net earnings. Non-cash charges added back $459K of depreciation and $4.3M of share-based compensation.
Questions
What was Ironwood Pharmaceuticals' revenue in the third quarter 2026?
Ironwood Pharmaceuticals (IRWD) reported revenue of $133M for the third quarter 2026 (Q3 2026), +9% from a year earlier and +18% from the quarter before.
Was Ironwood Pharmaceuticals profitable in the third quarter 2026?
Operating profit was $93.1M (70.0% of revenue) and net earnings $59.8M.